{"entity":{"id":"nct06998940","kind":"trial","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","aka":[],"tldr":"A phase 3 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and other drugs in pancreatic cancer, run by SWOG Cancer Research Network, now recruiting.","summary":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations is a phase 3, randomised interventional study registered as NCT06998940 by SWOG Cancer Research Network, with a registry enrolment figure of 94 participants, started 2026-05-13 and due to reach its primary completion in 2029-12-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Fluorouracil; Gemcitabine; Irinotecan; Irinotecan Sucrosofate; Leucovorin; Nab-paclitaxel; Panitumumab; Questionnaire Administration. Conditions listed: Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma. Primary outcome: Overall survival (OS). Pancreatic eligibility wording from the registry: \"* Participants must have a histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of the pancreas\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06998940","url":"https://clinicaltrials.gov/study/NCT06998940"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac","kras-wild-type-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["fluorouracil","gemcitabine","folfiri","flot","nab-paclitaxel","panitumumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06998940","phase":"3","setting":"Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma","sponsor":"SWOG Cancer Research Network","enrolled":94,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06998940/","neighbours":{"cancer":[{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}